Citalopram and metacognitive therapy for depressive symptoms and cognitive emotion regulation in patients with major depressive disorder: A randomized controlled trial
نویسندگان
1
2
3 Department of Epidemiology and Biostatistics, School of Public Health, Isfahan University of Medical Sciences, Isfahan, Iran
4
5
doi
چکیده
BACKGROUND: Metacognitive therapy (MCT) is a new psychotherapy for depression. Thisstudy was conducted to compare the effectiveness of citalopram and MCT on major depressivedisorders (MDDs).MATERIALS AND METHODS: A total of 36 patients with MDD were randomly assigned into threegroups of citalopram (n = 12), MCT (n = 16), and control (n = 8). MCT group received ten sessionsof metacognition therapy. Citalopram group received 20–40 mg citalopram, and the control groupdid not receive any interventions. Outcomes were measured using the Beck Depression Inventory‑II,Metacognition Questionnaire‑30, and Cognitive‑Emotion Regulation (CER) Questionnaire. Data wereanalyzed with ANCOVA using SPSS version 18.RESULTS: Depression score reduction was significant in both citalopram and metacognitivegroups (P < 0.05). However, there was only a statistically significant difference between MCT andcontrol group in CER and metacognition.CONCLUSION: MCT and citalopram both are effective in symptom reduction in MDD. Furthermore,MCT could lead to more improvement in metacognition, depression symptoms, and CER thancitalopram, when treating MDDs.
